TACC3 and osteosarcoma: Additionally, TACC3 exerts as a prognostic biomarker for prostate cancer (Qie, et al., 2020), osteosarcoma (Matsuda, et al., 2018) and NSCLC (Jiang, et al., 2016), and high TACC3 expression is associated with increased immune cell infiltration and T cell exhaustion (Fan, et al., 2021).